Skip to main content

Table 2 Index year and AED

From: Health care cost associated with the use of enzyme-inducing and non-enzyme–active antiepileptic drugs in the UK: a long-term retrospective matched cohort study

 

Overall population

Matched population

EIAED

(n = 2752)

nEAAED

(n = 2137)

p valuea

EIAED

(n = 951)

nEAAED

(n = 951)

p valuea

Year of index, n (%)

 

<0.0001

 

0.0669

 2001

298 (10.8)

70 (3.3)

 

45 (4.7)

55 (5.8)

 

 2002

326 (11.8)

88 (4.1)

53 (5.6)

63 (6.6)

 2003

312 (11.3)

121 (5.7)

86 (9.0)

72 (7.6)

 2004

402 (14.6)

147 (6.9)

109 (11.5)

85 (8.9)

 2005

314 (11.4)

190 (8.9)

106 (11.1)

96 (10.1)

 2006

275 (10.0)

222 (10.4)

121 (12.7)

109 (11.5)

 2007

256 (9.3)

255 (11.9)

121 (12.7)

119 (12.5)

 2008

225 (8.2)

293 (13.7)

106 (11.1)

123 (12.9)

 2009

206 (7.5)

371 (17.4)

130 (13.7)

119 (12.5)

 2010

138 (5.0)

380 (17.8)

74 (7.8)

110 (11.6)

Index AED, n (%)

<0.0001

 

<0.0001

EIAED cohort

 Carbamazepine

1742 (63.3)

 

690 (72.6)

 

 Phenytoin

971 (35.3)

245 (25.8)

 Phenobarbital

26 (0.9)

9 (0.9)

 Primidone

13 (0.5)

7 (0.7)

nEAAED cohort

 

 Lamotrigine

1239 (58.0)

632 (66.5)

 Gabapentin

448 (21.0)

149 (15.7)

 Levetiracetam

261 (12.2)

126 (13.2)

 Pregabalin

185 (8.7)

41 (4.3)

 Zonisamide

2 (0.1)

2 (0.2)

 Vigabatrin

2 (0.1)

1 (0.1)

  1. Abbreviations: AED antiepileptic drug, EIAED enzyme-inducing antiepileptic drug, nEAAED non-enzyme–active antiepileptic drug
  2. aChi-square test